ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IRIX / news
ITOC (33) NDRA (36) QTI (29) POCI (31) ⌘ Pro Terminal →

Why IRIX Stock advanced +1.33% Today — RQD Quant Desk Flash

$0.72 +1.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.72

IRIDEX Corporation (IRIX) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $12.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IRIX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IRIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, IRIDEX Corporation (NASDAQ: IRIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $0.72 (+1.33% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IRIX ranks #891 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IRIX compare to ITOC and NDRA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), IRIX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 36.5%, and ROIC of -35.0%. By comparison, ITOC (iTonic Holdings Ltd (Class A)) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $17.2M) and NDRA (ENDRA Life Sciences Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $7.2M). Among the 5-stock peer group, IRIX leads on earnings multiple (N/A) while IRIX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IRIX?
▼

Per IRIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-03, CIK 0001006045), IRIDEX Corporation generated $52.7M in revenue (+8.2% YoY), -$4.4M in net income, and -$2.3M in free cash flow against $29.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.72 (+0.05%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (5)Whales (7)SEC (8)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.9% Base Target
$2 Bull$1 Base$0 Bear
📬 FREE IRIX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRIX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY IRIX SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$0.82-6.1% Next Q
Q2 (-2Q)
32
Grade E$0.77-2.6% Next Q
Q3 (-1Q)
30
Grade E$0.75-4% Next Q
Current
27
Grade E$0.72-10.3% Hist 90D α
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IRIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IRIX currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.72) and Max Pain ($0.76) forces dealer call-delta covering toward $1.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IRIX Beats Next Quarter EPS Consensus (Jan 2, 2027) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why IRIX Stock advanced +1.33% Today — RQD Quant Desk Flash

IRIDEX Corporation (IRIX) advanced +1.33% to $0.72, trading at 11% of its 52-week range ($0.61 – $1.65). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 11% of its 52-week range ($0.61 – $1.65) with RSI-14 at 44.9 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.72 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 36.5% gross margin and $0 annual free cash flow.
Live IRIX Headlines & Catalysts
CATALYSTwww.marketscreener.com • 2d ago
Top Premarket Gainers

www.marketscreener.com report covering IRIDEX Corporation (IRIX) market action, institutional positioning, and fundamental catalysts.

MARKET WIREBenzinga • 8d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday&#39;s pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company&#39;s market cap stands at $1.9

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IRIX)

  • ✓Walkthrough of IRIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IRIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.43%▼ DESCENDING CHANNEL
2026-11-04O $0.71H $0.72L $0.71C $0.72VOL 19.1K
RES: $0.97SUP: $0.44SMA50: $0.72SMA200: $1.03
$1.24$1.07$0.90$0.73$0.56RES $0.97SUP $0.44$0.722026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRIX Butterfly Map → + Track IRIX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +8.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IRIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IRIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRIX)

Health Care Rank #891 of 1015 ⚔️ ITOC vs IRIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRIX vs. ITOC, NDRA, QTI, POCI)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, IRIDEX Corporation (IRIX) ranks #891 by composite RQD confidence (27/100, grade E) and #866 by equity capitalization ($12.7M). Within this direct 5-issuer industry benchmark cohort, IRIX leads on earnings valuation at N/A trailing P/E, while IRIX leads on capital efficiency and profitability with -35.0% ROIC and 36.5% gross margin. NDRA currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with IRIX at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IRIX ACTIVE
IRIDEX Corporation
E 27/100 — 36.5% -35.0% +1.33% $12.7M Benchmark Subject
ITOC
iTonic Holdings Ltd (Class A)
E 33/100 — 62.6% -35.0% -9.61% $17.2M /itoc-vs-irix →
NDRA
ENDRA Life Sciences Inc.
D- 36/100 — — -35.0% +1.05% $7.2M /ndra-vs-irix →
QTI
QT Imaging Holdings Inc.
E 29/100 — 45.4% -35.0% +0.47% $31.5M /qti-vs-irix →
POCI
Precision Optics Corporation Inc.
E 31/100 — 17.8% -35.0% +3.23% $52.8M /poci-vs-irix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-01-03 • CIK 0001006045 ↗

In its most recent audited fiscal period (FY2025, filed 2026-01-03), IRIDEX Corporation (IRIX) reported GAAP revenue of $52.7M (+8.2% vs. FY2024 revenue of $48.7M , and +1.6% cumulative change since FY2023) , GAAP net income of -$4.4M, operating cash flow of -$2.1M, and free cash flow of -$2.3M (+69.1% YoY). On the balance sheet, IRIX closed FY2025 with $29.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-01-03 $52.7M -$4.4M -$2.1M -$2.3M $29.2M —
FY2024 (FY) 2025-12-28 $48.7M -$8.9M -$7.3M -$7.3M $29.1M —
FY2023 (FY) 2024-12-30 $51.9M -$9.6M -$6.7M -$6.7M — —

3. IRIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, IRIDEX Corporation (NASDAQ: IRIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $0.72 (+1.33% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IRIX ranks #891 in composite RQD confidence.

How does IRIX compare to ITOC and NDRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), IRIX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 36.5%, and ROIC of -35.0%. By comparison, ITOC (iTonic Holdings Ltd (Class A)) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $17.2M) and NDRA (ENDRA Life Sciences Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $7.2M). Among the 5-stock peer group, IRIX leads on earnings multiple (N/A) while IRIX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IRIX?

Per IRIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-03, CIK 0001006045), IRIDEX Corporation generated $52.7M in revenue (+8.2% YoY), -$4.4M in net income, and -$2.3M in free cash flow against $29.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IRIX trading relative to its 50-day, 200-day, and 52-week technical levels?

IRIX last traded at $0.72 (+1.33% on volume of 19,121 shares), positioning the stock 0.00% above its 50-day simple moving average ($0.72) and -30.10% below its 200-day simple moving average ($1.03). Across its 52-week range of $0.61 to $1.65, IRIX sits at the 10.6% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.81).

Direct Sub-Reports: IRIX RQD Cockpit IRIX 12M Forecast IRIX Earnings & Move IRIX Dividends & DRIP IRIX Insiders & 13F IRIX Whale Options IRIX Profit Sankey IRIX News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

IRIX — IRIDEX Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-01-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

IRIDEX Corporation (IRIX) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.72 (+1.33% 1D, market capitalization $12.7M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 36.5%, operating margin of -4.9%, and free cash flow yield of -17.75%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

IRIDEX Corporation (IRIX) is listed on NASDAQ and classified in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Per the recent news wire, the company completed the relocation of its manufacturing facility to San Jose, California..0B, which is inconsistent with the $12.7M figure in the market data section and should be treated with caution.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-01-03), IRIDEX Corporation (IRIX) reported $52.7M in annual revenue (up from $48.7M in FY2024, +8.2% YoY) and -$4.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($51.9M revenue, -$9.6M net income) through FY2025, IRIX scaled operating cash flow to -$2.1M and free cash flow to -$2.3M, backed by $29.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.75% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $0.61 – $1.65 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -4.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), IRIX carries a macro regime beta of 1.00 and gross margin of 36.5%.

  • Key Question #1: Can IRIX sustain or expand its -4.9% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $52.7M and free cash flow of -$2.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is IRIX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IRIX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for IRIDEX Corporation (IRIX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IRIX Debate Forum (3) ↓
🟢 CATALYST www.marketscreener.com • 2d ago
Top Premarket Gainers

www.marketscreener.com report covering IRIDEX Corporation (IRIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IRIX Bull vs. Bear Conversation Board — What's Your Call at $0.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IRIX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IRIX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $0.89 (+25.4%)
📌 Pinned Debate

Cash rose from $2.4M in FY 2024 to $6.0M in FY 2025 while operating losses narrowed, per the SEC financials.

Long IRIX at $0.71 targeting $0.89. Cash rose from $2.4M in FY 2024 to $6.0M in FY 2025 while operating losses narrowed, per the SEC financials.. Institutional whale score is 7/20 and the risk/reward vs. the $0.61 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — IRIX's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $0.55 (-22.5%)
Spot @ $0.71

ROIC of -35% and an FCF yield of -17.75% alongside an Altman Z of 0.2 signal a cash-consuming business with distress-level balance shee

Fading this rally in IRIX at $0.71. ROIC of -35% and an FCF yield of -17.75% alongside an Altman Z of 0.2 signal a cash-consuming business with distress-level balance sheet risk.. With a beta of 1.0 and the stock sitting at $0.71 (52-wk range $0.61–$1.65), the easy multiple expansion is already priced in.

LIVE TAPE